IRIS
TASSONE, PIERFRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.438
AS - Asia 6.220
EU - Europa 3.089
SA - Sud America 1.475
Continente sconosciuto - Info sul continente non disponibili 364
AF - Africa 139
OC - Oceania 21
Totale 20.746
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.058
SG - Singapore 2.816
IT - Italia 1.464
CN - Cina 1.412
BR - Brasile 1.092
VN - Vietnam 643
IN - India 621
SE - Svezia 406
GB - Regno Unito 380
DE - Germania 282
CA - Canada 262
HK - Hong Kong 150
AR - Argentina 136
FI - Finlandia 110
BD - Bangladesh 109
ID - Indonesia 84
EC - Ecuador 72
MX - Messico 71
NL - Olanda 67
FR - Francia 53
IQ - Iraq 52
RU - Federazione Russa 52
UA - Ucraina 45
CO - Colombia 43
PK - Pakistan 42
ES - Italia 40
RO - Romania 40
ZA - Sudafrica 35
JO - Giordania 33
JP - Giappone 33
CL - Cile 32
PY - Paraguay 32
SA - Arabia Saudita 31
VE - Venezuela 30
TR - Turchia 29
PL - Polonia 27
EG - Egitto 24
EU - Europa 22
IR - Iran 22
PE - Perù 21
CZ - Repubblica Ceca 19
LT - Lituania 16
AE - Emirati Arabi Uniti 15
AT - Austria 15
IE - Irlanda 15
MA - Marocco 15
AU - Australia 14
MY - Malesia 14
KE - Kenya 13
UY - Uruguay 13
UZ - Uzbekistan 13
KR - Corea 12
TN - Tunisia 11
KZ - Kazakistan 10
PT - Portogallo 10
PH - Filippine 9
AZ - Azerbaigian 8
EE - Estonia 8
ET - Etiopia 8
IL - Israele 8
LB - Libano 8
NG - Nigeria 8
CH - Svizzera 7
DZ - Algeria 7
GT - Guatemala 7
HN - Honduras 7
SN - Senegal 7
BG - Bulgaria 6
DO - Repubblica Dominicana 6
JM - Giamaica 6
NP - Nepal 6
CY - Cipro 5
PS - Palestinian Territory 5
TT - Trinidad e Tobago 5
TW - Taiwan 5
CR - Costa Rica 4
NI - Nicaragua 4
NZ - Nuova Zelanda 4
AL - Albania 3
BN - Brunei Darussalam 3
GE - Georgia 3
GR - Grecia 3
HR - Croazia 3
HU - Ungheria 3
KG - Kirghizistan 3
KW - Kuwait 3
LK - Sri Lanka 3
LV - Lettonia 3
MD - Moldavia 3
OM - Oman 3
PA - Panama 3
SC - Seychelles 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BO - Bolivia 2
GY - Guiana 2
KI - Kiribati 2
PR - Porto Rico 2
Totale 20.385
Salva come PNG Salva come JPEG
Città #
San Jose 1.743
Chandler 906
Singapore 888
Ashburn 825
Dallas 510
Santa Clara 498
Hefei 429
Bengaluru 428
Milan 400
Lawrence 383
Princeton 383
Council Bluffs 350
Chicago 273
London 255
Ho Chi Minh City 252
Beijing 249
Wilmington 224
Munich 211
Ottawa 165
Catanzaro 158
Hong Kong 137
Hanoi 125
Des Moines 111
Los Angeles 96
São Paulo 90
Boardman 85
New York 79
Turku 73
Rome 65
Shanghai 51
Rio de Janeiro 44
Guangzhou 42
Naples 42
Pune 40
Helsinki 36
The Dalles 34
Brooklyn 32
Norwalk 32
San Francisco 32
Haiphong 30
Redwood City 30
Montreal 28
Redmond 28
Da Nang 26
Amman 25
Chennai 25
Biên Hòa 24
Quito 24
Warsaw 23
Manchester 21
Orem 21
Parma 21
Phoenix 21
Atlanta 20
Baghdad 20
Boston 20
Tokyo 20
Columbus 19
Curitiba 19
Mexico City 19
Jeddah 18
Stockholm 18
Thái Bình 18
Denver 17
Guayaquil 17
Salvador 17
Charlotte 16
San Nicola Manfredi 16
Aversa 15
Delhi 15
Dhaka 15
Porto Alegre 15
Amsterdam 14
Buffalo 14
Olomouc 14
Reggio Calabria 14
West Jordan 14
Brasília 13
Campinas 13
Horia 13
Johannesburg 13
Madrid 13
Mountain View 13
Tashkent 13
Washington 13
Belo Horizonte 12
Buenos Aires 12
Carbonia 12
Frankfurt am Main 12
Las Vegas 12
Montevideo 12
Nairobi 12
Palermo 12
Recife 12
Seattle 12
Thái Nguyên 12
Timisoara 12
Vallefiorita 12
Augusta 11
Bogotá 11
Totale 11.809
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 497
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 146
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 119
miR-22 suppresses DNA ligase III addiction in multiple myeloma 108
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience 102
An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity 100
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 100
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 98
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 93
A 5 ' regulatory sequence containing two Ets motifs controls the expression of the Wiskott-Aldrich syndrome protein (WASP) gene in human hematopoietic cells 90
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 89
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 89
Aberrant Glycosylation as Biomarker for Cancer: Focus on CD43 88
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 87
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease 87
Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer 85
Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report 84
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 84
277 POSTER An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity 83
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 83
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 82
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 82
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 79
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 79
Pyrrolo[2′,3′:3,4]cyclohepta[1,2- d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types 79
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 78
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 78
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 78
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 77
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 77
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 77
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 77
Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients 76
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 76
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma 75
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 75
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 74
Fetal ontogeny and tumor expression of the early thymic antigen UN1 74
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 74
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 74
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 74
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 74
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 74
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 74
Mir-34: a new weapon against cancer? 72
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 72
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 71
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 71
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 70
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 70
Differential microRNAs expression profile in coronary thrombi from patients with no-reflow after primary PCI 69
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 69
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 68
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 68
Associazione di antagonisti di IL-6 e farmaci anti-proliferativi (depositato il 10.3.2005 n. RM2005A000103) 68
A novel monoclonal antibody recognizing human thymocytes and B-cell chronic lymphocytic leukemia cells 68
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 67
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 67
Biochemical modification of an Interleukin-6 antagonist to target myeloma cells in the bone marrow microenvironment 67
Molecular and clinical types of plasma cell dyscrasias are associated with distinct expression patterns of long noncoding RNAs 67
Oleil hydroxytyrosol (Htol) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells (CO-FIRST AUTHOR) 67
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 66
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 66
Modeling UGT2B7 and NR1I3 genes through multilayer network to highlight hidden link with taxane neurotoxicity 65
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 65
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 65
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 65
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 65
Transcriptional regulation of the mismatch repair gene hMLH1 64
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 64
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 63
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth 62
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 62
miR-221/222 inhibitors for the treatment of multiple myeloma 62
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 62
Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin's Lymphoma 61
Mir-221/222 are promising targets for innovative anticancer therapy 61
Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia 61
Genes specifically expressed during early stages of haemopoietic differentiation detected by DDRT-PCR. 61
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 61
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives 60
HLA class I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells 60
Liposomes containing zoledronic acid: A new opportunity against cancer 60
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients 60
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 60
Anti-myeloma activity of miR-125 mimics 60
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 59
Bioinformatic challenges for pharmacogenomic study: tools for genomic data analysis 59
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma 59
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation 59
[Extended subcutaneous mastectomy. A new type of operation in non-destructive surgery of breast neoplasms]. FT La mastectomia sottocutanea allargata. Un nuovo tipo d'intervento nella chirurgia non demolitiva della neoplasia mammaria. 59
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 59
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 59
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 59
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 58
Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides. 58
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of cancer 58
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? 58
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 58
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 58
Totale 7.701
Salva come PNG Salva come JPEG
Categoria #
all - tutte 205.993
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 205.993
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.124 0 6 17 333 87 20 29 249 114 97 149 23
2022/20232.838 787 108 110 204 299 234 23 198 425 171 228 51
2023/20241.557 347 158 127 110 104 379 45 61 13 51 65 97
2024/20254.484 615 274 203 134 251 564 126 163 510 266 448 930
2025/20269.335 454 966 1.028 1.709 916 362 1.222 549 1.072 635 265 157
2026/2027515 122 393 0 0 0 0 0 0 0 0 0 0
Totale 20.746